-
Comparison of the cutaneous iontophoretic delivery of rasagiline and selegiline across porcine and human skin in vitro.
International journal of pharmaceutics 20121115
-
Rasagiline: a guide to its use in Parkinson's disease.
CNS drugs 20120901
-
Proteoliposome-based capillary electrophoresis for screening membrane protein inhibitors.
Journal of chromatographic science 20120801
-
Indirect comparisons of adverse events and dropout rates in early Parkinson's disease trials of pramipexole, ropinirole, and rasagiline.
The International journal of neuroscience 20120701
-
Drugs for treating Parkinson disease.
Nursing 20120701
-
Development of Parkinson's disease in patients with Narcolepsy.
Journal of neural transmission (Vienna, Austria : 1996) 20120601
-
Hyposmia in Parkinson's disease.
Psychiatry and clinical neurosciences 20120601
-
Livedo reticularis associated with rasagiline (azilect).
Journal of drugs in dermatology : JDD 20120601
-
The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?
Journal of clinical pharmacology 20120501
-
Synthesis and evaluation of [¹⁸F]fluororasagiline, a novel positron emission tomography (PET) radioligand for monoamine oxidase B (MAO-B).
Bioorganic & medicinal chemistry 20120501
-
Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase.
Journal of neural transmission (Vienna, Austria : 1996) 20120401
-
Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.
Drugs 20120326
-
Rasagiline interferes with neurodegeneration in the Prph2/rds mouse.
Retina (Philadelphia, Pa.) 20120301
-
Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.
European journal of neurology 20120201
-
From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease.
Journal of Alzheimer's disease : JAD 20120101
-
Restless legs syndrome responsive to rasagiline treatment: a case report.
Clinical neuropharmacology 20120101
-
Combined beneficial effect of rasagiline on motor function and depression in de novo PD.
Clinical neuropharmacology 20120101
-
Drugs in traffic: the road to approval.
Nature medicine 20111206
-
Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.
European journal of neurology 20111201
-
Reversible Pisa syndrome in patients with Parkinson's disease on rasagiline therapy.
Movement disorders : official journal of the Movement Disorder Society 20111201
-
Effect of rasagiline on the molecular composition of the excitatory postsynaptic density.
European journal of pharmacology 20111130
-
Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline.
Movement disorders : official journal of the Movement Disorder Society 20111101
-
Rasagiline: time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment.
The neurologist 20111101
-
An effective novel delivery strategy of rasagiline for Parkinson's disease.
International journal of pharmaceutics 20111031
-
Determining the efficacy of rasagiline in reducing bradykinesia among Parkinson's disease patients: a review.
The International journal of neuroscience 20110901
-
The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study.
Movement disorders : official journal of the Movement Disorder Society 20110815
-
Safety of rasagiline for the treatment of Parkinson's disease.
Expert opinion on drug safety 20110701
-
TVP1022 attenuates cardiac remodeling and kidney dysfunction in experimental volume overload-induced congestive heart failure.
Circulation. Heart failure 20110701
-
The cardioprotective efficacy of TVP1022 in a rat model of ischaemia/reperfusion.
British journal of pharmacology 20110601
-
Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease.
Expert opinion on pharmacotherapy 20110601
-
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
The Lancet. Neurology 20110501
-
MIND-BEST: Web server for drugs and target discovery; design, synthesis, and assay of MAO-B inhibitors and theoretical-experimental study of G3PDH protein from Trichomonas gallinae.
Journal of proteome research 20110401
-
Determination of minimal clinically important change in early and advanced Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 20110401
-
Does 1-(R)-aminoindan possess neuroprotective properties against experimental Parkinson's disease?
Antioxidants & redox signaling 20110301
-
Hemiparkinsonism-hemiatrophy syndrome.
Archives of Iranian medicine 20110301
-
Rasagiline-induced serotonin syndrome.
Movement disorders : official journal of the Movement Disorder Society 20110301
-
Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: An economic Markov model evaluation.
Drugs & aging 20110201
-
MAO inhibitors.
Cleveland Clinic journal of medicine 20110201
-
Rasagiline-induced delay of retinal ganglion cell death in experimental glaucoma in rats.
Journal of glaucoma 20110101
-
Selegiline and rasagiline: twins or distant cousins?
The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20110101
-
Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro.
BMC pharmacology 20110101
-
Targeting monoamine oxidases with multipotent ligands: an emerging strategy in the search of new drugs against neurodegenerative diseases.
Current medicinal chemistry 20110101
-
[The role of the MAO-B inhibitor razagiline in the treatment of Parkinson's disease].
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20110101
-
Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease.
International review of neurobiology 20110101
-
Rasagiline in Parkinson's disease.
International review of neurobiology 20110101
-
Selective inhibitors of monoamine oxidase type B and the 'cheese effect'.
International review of neurobiology 20110101
-
Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline.
Journal of clinical pharmacology 20101201
-
Site-activated chelators derived from anti-Parkinson drug rasagiline as a potential safer and more effective approach to the treatment of Alzheimer's disease.
Neurochemical research 20101201
-
The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?
Neurology 20101123
-
The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?
Neurology 20101123
-
Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.
Progress in neurobiology 20101101
-
Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells.
Neurochemistry international 20101101
-
[Rasagiline: effectiveness and protection in Parkinson's disease].
Revista de neurologia 20101101
-
[Disease-modifying therapies in PD].
Rinsho shinkeigaku = Clinical neurology 20101101
-
Efficacy and tolerability of rasagiline in daily clinical use--a post-marketing observational study in patients with Parkinson's disease.
European journal of neurology 20100901
-
Isolated delusional syndrome in Parkinson's Disease.
Parkinsonism & related disorders 20100901
-
Slowing the decline.
Nature 20100826
-
Rasagiline improves learning and memory in young healthy rats.
Behavioural pharmacology 20100701
-
Discordant effects of rasagiline doses in Parkinson disease.
Nature reviews. Neurology 20100701
-
Long-term efficacy of rasagiline in early Parkinson's disease.
The International journal of neuroscience 20100601
-
Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?
Neurology 20100406
-
The delayed-start study in Parkinson disease: can't satisfy everyone.
Neurology 20100406
-
Reply to Drs. Olanow and Rascol.
Neurology 20100406
-
The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline.
Journal of neurochemistry 20100301
-
[On the role of MAO B inhibitors and NMDA antagonists in the therapy of Parkinson's disease].
Fortschritte der Neurologie-Psychiatrie 20100301
-
Parkinson disease: ADAGIO trial hints that rasagiline slows disease progression.
Nature reviews. Neurology 20100301
-
Parkinson's disease: health-related quality of life, economic cost, and implications of early treatment.
The American journal of managed care 20100301
-
Rasagiline in Parkinson's disease.
The New England journal of medicine 20100218
-
Rasagiline in Parkinson's disease.
The New England journal of medicine 20100218
-
TVP1022 protects neonatal rat ventricular myocytes against doxorubicin-induced functional derangements.
The Journal of pharmacology and experimental therapeutics 20100201
-
Selective MAO-B inhibitors have low potential for the tyramine effect.
Movement disorders : official journal of the Movement Disorder Society 20100115
-
Low dosage of rasagiline and epigallocatechin gallate synergistically restored the nigrostriatal axis in MPTP-induced parkinsonism.
Neuro-degenerative diseases 20100101
-
The role of rasagiline in the treatment of Parkinson's disease.
Clinical interventions in aging 20100101
-
What is the clinical significance of the findings from the delayed-start trial of rasagiline in Parkinson's disease?
Neuroepidemiology 20100101
-
Delayed start, rapid solution?
Neuroepidemiology 20100101
-
Electropharmacograms of rasagiline, its metabolite aminoindan and selegiline in the freely moving rat.
Neuropsychobiology 20100101
-
Treatment of advanced Parkinson's disease in the United States: a cost-utility model.
Clinical drug investigation 20100101
-
[Rasagiline is not for all Parkinson disease patients: the ADAGIO study].
Nederlands tijdschrift voor geneeskunde 20100101
-
[Efficacy of rasagiline in patients with advanced Parkinson's disease with motor fluctuation (azimut study)].
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20100101
-
Mao-B inhibitor know-how: back to the pharm.
Neurology 20091208
-
Lack of clinically significant interactions between concomitantly administered rasagiline and escitalopram.
Progress in neuro-psychopharmacology & biological psychiatry 20091113
-
Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson's disease drug, rasagiline compared with selegiline, in the rat midbrain.
Journal of neural transmission (Vienna, Austria : 1996) 20091101
-
Rasagiline-induced spontaneous ejaculation.
Movement disorders : official journal of the Movement Disorder Society 20091030
-
A double-blind, delayed-start trial of rasagiline in Parkinson's disease.
The New England journal of medicine 20090924
-
Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan.
Neurotoxicity research 20090801
-
Development and validation of a reverse phase liquid chromatography method for the quantification of rasagiline mesylate in biodegradable PLGA microspheres.
Journal of pharmaceutical and biomedical analysis 20090712
-
Validation of the freezing of gait questionnaire in patients with Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 20090415
-
MAO-B inhibitor know-how: back to the pharm.
Neurology 20090414
-
Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis.
Neurotoxicity research 20090401
-
Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 20090315
-
Neuroprotection by rasagiline in thiamine deficient rats.
Brain research 20090223
-
Mechanisms compensating for dopamine loss in early Parkinson disease.
Neurology 20090217
-
[Neuroprotection in Parkinson's disease and other neurodegenerative disorders: preclinical and clinical findings].
Ideggyogyaszati szemle 20090130
-
Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 20090101
-
Investigation of oral selegiline and rasagiline administration on QT interval in conscious rabbits.
European review for medical and pharmacological sciences 20090101
-
[Clinical manifestation of confusion and hallucinations caused by an interaction between rasagiline and escitalopram].
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20090101
-
Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation.
Drugs & aging 20090101
-
Sleep attack associated to rotigotine.
Clinical neuropharmacology 20090101
-
Drug selection and timing of initiation of treatment in early Parkinson's disease.
Annals of neurology 20081201
-
A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics.
Movement disorders : official journal of the Movement Disorder Society 20081115
-
Rapid and sensitive liquid chromatography-tandem mass spectrometry: assay development, validation and application to a human pharmacokinetic study.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20081115
-
The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy.
Expert opinion on pharmacotherapy 20081101
-
Rasagiline ethanedisulfonate: an inhibitor for monoamine oxygenase B (MAO(B)).
Acta crystallographica. Section C, Crystal structure communications 20081101
-
Validated LC-MS/MS method for quantitative determination of rasagiline in human plasma and its application to a pharmacokinetic study.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20081001
-
[Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Fortschritte der Neurologie-Psychiatrie 20081001
-
Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease.
Hypertension (Dallas, Tex. : 1979) 20080901
-
TVP1022 and propargylamine protect neonatal rat ventricular myocytes against doxorubicin-induced and serum starvation-induced cardiotoxicity.
Journal of cardiovascular pharmacology 20080901
-
Rasagiline in neurodegeneration.
Experimental neurology 20080801
-
Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration.
Journal of neurochemistry 20080601
-
[Rasagiline in Parkinson's disease].
Neurologia (Barcelona, Spain) 20080501
-
Rasagiline is neuroprotective in a transgenic model of multiple system atrophy.
Experimental neurology 20080401
-
[A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508].
Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology 20080301
-
Rasagiline improves freezing in a patient with primary progressive freezing gait.
Movement disorders : official journal of the Movement Disorder Society 20080215
-
Molecular dynamics, flexible docking, virtual screening, ADMET predictions, and molecular interaction field studies to design novel potential MAO-B inhibitors.
Journal of biomolecular structure & dynamics 20080201
-
Differential behavioral syndrome evoked in the rats after multiple doses of SSRI fluoxetine with selective MAO inhibitors rasagiline or selegiline.
Journal of neural transmission (Vienna, Austria : 1996) 20080101
-
[The use of a new MAO B inhibitor rasagiline in the treatment of motor fluctuations in Parkinson's disease].
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20080101
-
Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
Pharmacotherapy 20071201
-
Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy.
Annals of the New York Academy of Sciences 20071201
-
Parkinson disease: an incremental challenge.
South Dakota medicine : the journal of the South Dakota State Medical Association 20071201
-
Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro.
Journal of neurochemistry 20071001
-
Rasagiline promotes regeneration of substantia nigra dopaminergic neurons in post-MPTP-induced Parkinsonism via activation of tyrosine kinase receptor signaling pathway.
Neurochemical research 20071001
-
Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Clinical therapeutics 20070901
-
The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by two series of novel carbamates.
Molecular pharmacology 20070601
-
Rasagiline as a therapy for Parkinson's disease (PD).
The American journal of geriatric pharmacotherapy 20070601
-
Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism.
Neurobiology of disease 20070101
-
Rasagiline is neuroprotective in an experimental model of brain ischemia in the rat.
Journal of neural transmission (Vienna, Austria : 1996) 20070101
-
Rasagiline: a review of its use in the management of Parkinson's disease.
Drugs 20070101
-
Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors.
Drugs & aging 20070101
-
Neuroprotection by propargylamines in Parkinson's disease: intracellular mechanism underlying the anti-apoptotic function and search for clinical markers.
Journal of neural transmission. Supplementum 20070101
-
Rasagiline (Azilect) for Parkinson's disease.
The Medical letter on drugs and therapeutics 20061204
-
L-methamphetamine and selective MAO inhibitors decrease morphine-reinforced and non-reinforced behavior in rats; Insights towards selegiline's mechanism of action.
Pharmacology, biochemistry, and behavior 20061201
-
The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30.
Current Alzheimer research 20061201
-
Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
The American journal of geriatric pharmacotherapy 20061201
-
Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms.
Journal of the neurological sciences 20061025
-
Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.
Movement disorders : official journal of the Movement Disorder Society 20061001
-
Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease.
Neurology 20060523
-
Clinical trials with rasagiline: evidence for short-term and long-term effects.
Neurology 20060523
-
Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20060515
-
[Diagnosis and therapy of idiopathic Parkinson's disease].
MMW Fortschritte der Medizin 20060515
-
Safety of rasagiline in elderly patients with Parkinson disease.
Neurology 20060509
-
Rasagiline improves quality of life in patients with early Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 20060501
-
Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.
The Annals of pharmacotherapy 20060401
-
Rasagiline -- is there a place for this drug in managing Parkinson's disease?
International journal of clinical practice 20060201
-
Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease.
International journal of clinical practice 20060201
-
Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness.
British journal of pharmacology 20060101
-
Concerning neuroprotective therapy for Parkinson's disease.
Journal of neural transmission. Supplementum 20060101
-
Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety.
Journal of neural transmission. Supplementum 20060101
-
New drugs: rasagiline mesylate, conivaptan hydrochloride, and sunitinib malate.
Journal of the American Pharmacists Association : JAPhA 20060101
-
New drug treatment for Parkinson's disease.
FDA consumer 20060101
-
Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection.
Journal of neural transmission. Supplementum 20060101
-
The use of rasagiline in Parkinson's disease.
Journal of neural transmission. Supplementum 20060101
-
Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis.
Journal of medicinal chemistry 20051229
-
Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20051101
-
Present and future drug treatment for Parkinson's disease.
Journal of neurology, neurosurgery, and psychiatry 20051101
-
Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
Expert review of neurotherapeutics 20051101
-
Rasagiline in the pharmacotherapy of Parkinson's disease--a review.
Expert opinion on pharmacotherapy 20051001
-
In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PET.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20051001
-
[Rasagiline in motor fluctuations].
Fortschritte der Neurologie-Psychiatrie 20050901
-
Neuroprotective effect of rasagiline, a monoamine oxidase-B inhibitor, on spontaneous cell degeneration in a rat model.
Journal of neural transmission (Vienna, Austria : 1996) 20050801
-
Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease.
Journal of clinical pharmacology 20050801
-
Reexamination of the TEMPO Study.
Archives of neurology 20050801
-
Rasagiline.
Nature reviews. Drug discovery 20050801
-
Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway.
Annals of the New York Academy of Sciences 20050801
-
[Rasagiline. A new monoamine oxidase b inhibitor for Parkinson treatment].
Medizinische Monatsschrift fur Pharmazeuten 20050701
-
Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline.
Drugs of today (Barcelona, Spain : 1998) 20050601
-
Parkinson's disease. Diagnosis and the initiation of therapy.
Minerva medica 20050601
-
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
Movement disorders : official journal of the Movement Disorder Society 20050501
-
Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives.
Brain research. Brain research reviews 20050401
-
Novel pharmacological strategies for motor complications in Parkinson's disease.
Expert opinion on investigational drugs 20050401
-
Characterization of the neuroprotective activity of rasagiline in cerebellar granule cells.
Neuropharmacology 20050301
-
Rasagiline for motor complications in Parkinson's disease.
Lancet (London, England) 20050301
-
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
Lancet (London, England) 20050301
-
Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Mechanisms of ageing and development 20050201
-
A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
Archives of neurology 20050201
-
Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition.
Journal of neuroscience research 20050101
-
Movement disorders: understanding clinical trials.
The Lancet. Neurology 20050101
-
Rasagiline.
Drugs & aging 20050101
-
Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy.
Movement disorders : official journal of the Movement Disorder Society 20050101
-
Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease?
CNS drug reviews 20050101
-
[The early therapy challenge].
Krankenpflege Journal 20050101
-
[Are there innovations in the treatment of Parkinson's disease?].
Praxis 20041103
-
Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.
Neurology 20041012
-
Clinical trials of neuroprotection for Parkinson's disease.
Neurology 20041012
-
Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline.
British journal of pharmacology 20041001
-
Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
Journal of neural transmission (Vienna, Austria : 1996) 20041001
-
Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor.
Pharmacotherapy 20041001
-
Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20040901
-
Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model.
Journal of neurology 20040901
-
Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.
Movement disorders : official journal of the Movement Disorder Society 20040801
-
Rasagiline enhances L-DOPA-induced contralateral turning in the unilateral 6-hydroxydopamine-lesioned guinea-pig.
Neuropharmacology 20040701
-
Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease.
Experimental neurology 20040601
-
Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo.
Journal of neurochemistry 20040601
-
N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor.
Neurochemistry international 20040501
-
A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.
Archives of neurology 20040401
-
Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues.
Journal of medicinal chemistry 20040325
-
Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class.
Journal of medicinal chemistry 20040325
-
Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline.
Neuroscience letters 20040130
-
Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease?
BioEssays : news and reviews in molecular, cellular and developmental biology 20040101
-
The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20031201
-
The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline.
Biochemical pharmacology 20031015
-
Amyloid processing and signal transduction properties of antiparkinson-antialzheimer neuroprotective drugs rasagiline and TV3326.
Annals of the New York Academy of Sciences 20030501
-
Synthesis and initial results for MAO-B inhibition by new N-propargyl-3-pyrrol-1-ylindanamine derivatives, analogues of rasagiline.
Journal of enzyme inhibition and medicinal chemistry 20030401
-
Monoamine oxidase inhibitors--is it time to up the TEMPO?
The Lancet. Neurology 20030301
-
A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.
Archives of neurology 20021201
-
Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours.
Neuropharmacology 20021201
-
Involvement of MAP kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20021001
-
Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan.
Journal of neurochemistry 20020801
-
Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial.
Movement disorders : official journal of the Movement Disorder Society 20020701
-
An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells.
Neuroscience letters 20020628
-
Rasagiline. Teva Pharmaceutical.
Current opinion in investigational drugs (London, England : 2000) 20020501
-
Mitochondria determine the survival and death in apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, and neuroprotection by propargylamines.
Journal of neural transmission (Vienna, Austria : 1996) 20020501
-
Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline.
Mechanisms of ageing and development 20020430
-
The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells.
Journal of neural transmission (Vienna, Austria : 1996) 20020401
-
Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease.
Parkinsonism & related disorders 20020301
-
Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].
Cellular and molecular neurobiology 20011201
-
Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol.
Journal of neurochemistry 20010801
-
Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs.
Annals of the New York Academy of Sciences 20010601
-
Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022.
Annals of the New York Academy of Sciences 20010601
-
The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo.
Annals of the New York Academy of Sciences 20010601
-
Do antioxidant strategies work against aging and age-associated disorders? Propargylamines: a possible antioxidant strategy.
Annals of the New York Academy of Sciences 20010401
-
Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B.
British journal of pharmacology 20010101
-
Rasagiline and its (S) enantiomer increase survival and prevent stroke in salt-loaded stroke-prone spontaneously hypertensive rats.
Journal of neural transmission (Vienna, Austria : 1996) 20010101
-
Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Journal of neural transmission (Vienna, Austria : 1996) 20010101
-
Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders.
Journal of neural transmission. Supplementum 19980101